Search the Newsreel

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside

Analysts have cut the 12-month average price target for Caribou Biosciences, Inc. stock from $12 to $11.86, with individual forecasts ranging from $4 to $32 per share. Despite the slight reduction in the average target, this still implies a significant 636% potential upside based …

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) reported a quarterly loss of $0.24 per share, surpassing analyst expectations by $0.08, though revenue of $1.50 million fell short of estimates. Following the announcement, shares declined by 5.3% to $1.61. Despite substantial losses and a negative net margin, institutional investors …

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) reported a Q2 loss of $0.24 per share, outperforming the Zacks Consensus Estimate of a $0.33 loss. However, the company missed revenue estimates, posting $1.5 million against an expected $2.5 million. The stock currently holds a Zacks Rank #3 (Hold), …

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences has released its financial results for the second quarter of 2026, alongside a business update. The report details the company's financial performance and highlights recent developments in its operations and strategic initiatives.

Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss

Caribou Biosciences reported its Q2 2026 financial results, showing $1.5 million in licensing revenue and a GAAP net loss of $24.3 million. The company holds $113.8 million in cash and expects these funds to support operations through the end of 2027. Business highlights include …

Caribou Biosciences Q2 Results: Net loss narrows to $24.3 million

Caribou Biosciences reported a narrowed net loss of $24.3 million in Q2 2026, significantly improving from $54.1 million in Q2 2025, beating EPS estimates. This was primarily due to a sharp decline in operating expenses and cost-cutting measures. However, quarterly sales missed analyst forecasts, …

Caribou Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Caribou Biosciences, Inc. has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement from Reuters, indicating that a full report is available to subscribers of TradingView.

Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients

Caribou Biosciences reported its Q2 2026 financial results and provided an update on its CAR-T pipeline. The company's vispa-cel therapy for large B cell lymphoma showed an 82% overall response rate, while CB-011 for multiple myeloma achieved a 92% overall response rate in a …

Caribou Biosciences, Inc. expected to post a loss of 32 cents a share - Earnings Preview

Caribou Biosciences, Inc. is expected to report an upcoming earnings loss. Analysts project the company to post a loss of 32 cents per share. This information is presented as an earnings preview.

Number of shareholders of Caribou Biosciences, Inc. – NASDAQ:CRBU

This page provides information regarding the number of shareholders for Caribou Biosciences, Inc. (NASDAQ: CRBU). It indicates that the data is available for a specific period, including its value and change percentage, and is provided by FactSet Research Systems Inc. The page is hosted …

Caribou Biosciences 1Q 2026: Revenue $2.4M, EPS ($0.26) — 10-Q Summary

Caribou Biosciences reported its first-quarter 2026 results, showing a modest increase in revenue to $2.4 million and a narrower net loss per share of ($0.26). This improvement was attributed to reduced R&D spending and strategic program prioritization, alongside significant clinical progress in its Vispa-cel …

Caribou Biosciences, Inc. $CRBU Stock Holdings Raised by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Caribou Biosciences (CRBU) by 58% in the first quarter, adding over 950,000 shares. Other major institutional investors like Millennium Management and Marshall Wace also raised their holdings, indicating strong institutional confidence with 77.51% ownership. Despite reporting …

Caribou Biosciences, Inc. (CRBU) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of Caribou Biosciences, Inc. (CRBU) stock, including its current price, news, and historical data. It lists recent articles from sources like Zacks and Insider Monkey, discussing earnings, analyst upgrades, and pipeline potential. The page also presents …

Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates

Caribou Biosciences (CRBU) to Announce Earnings on Wednesday

Caribou Biosciences (CRBU) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th, with analysts anticipating a loss of $0.33 per share and $2.28 million in revenue. The company's previous quarter beat expectations, reporting a smaller loss and higher …

Price to sales forward of Caribou Biosciences, Inc. – NASDAQ:CRBU

This article provides financial information for Caribou Biosciences, Inc. (NASDAQ: CRBU), specifically focusing on its forward price-to-sales ratio. It appears to be a data-driven snippet from a financial platform, offering a snapshot of a particular financial metric for the company. The content itself is …

Enterprise value to revenue forward of Caribou Biosciences, Inc. – NASDAQ:CRBU

This article focuses on the enterprise value to revenue forward for Caribou Biosciences, Inc. (NASDAQ: CRBU). It provides financial overview, and access to various financial tools and data provided by TradingView and its partners. The content also lists numerous features and services offered by …

Caribou Biosciences Inc (CRBU) Institutional Confidence

This article analyzes Caribou Biosciences Inc.'s (CRBU) institutional confidence score, which is currently 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 49.07% quarter-over-quarter to 36.25%. James Simons is the largest institutional shareholder, …

CRBU|Caribou Biosciences Inc|Price:1.455|Chg%:-0.035

This article provides a comprehensive stock analysis of Caribou Biosciences Inc (CRBU), highlighting its relatively stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite a recent downward trend in stock price and weak market performance, analysts mostly …

Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Caribou Biosciences Inc (CRBU), noting its current valuation score of 7.09, which ranks 256 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.12, while stating that P/B, P/S, …

Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Caribou Biosciences Inc (CRBU) focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years. The page also presents current stock data including market cap and …

Caribou Biosciences Inc (CRBU) Income Statement

This article provides the quarterly and annual income statements for Caribou Biosciences Inc (CRBU), offering detailed financial data such as total revenue, operating expenses, research and development costs, and net income. It allows users to gain insights into the company's financial performance and operational …

BlackRock (NYSE: BLK) reports 7.2% beneficial stake in Caribou Biosciences (CRBU)

Caribou Biosciences, Inc. Revenue Breakdown – NASDAQ:CRBU

Caribou Biosciences Inc. (NASDAQ: CRBU) generated $11.16 million USD in revenue last year, primarily from its Allogeneic Chimeric Antigen Receptor - T Cell Therapies segment. The United States was the largest contributor to its regional performance, accounting for $9.48 million USD of the revenue. …

Enterprise value to EBIT forward of Caribou Biosciences, Inc. – NASDAQ:CRBU

The article discusses the enterprise value to EBIT forward for Caribou Biosciences, Inc. (NASDAQ: CRBU), a biotechnology company listed on the Nasdaq Stock Market. It appears to be a financial data snippet from TradingView, which provides tools for market analysis and trading. The content …

Caribou Biosciences (NASDAQ:CRBU) Stock Price Up 1.9% - Time to Buy?